225 related articles for article (PubMed ID: 20496538)
41. Immunomodulatory agents for the treatment of cachexia.
Chasen M; Bhargava R; Hirschman S
Curr Opin Support Palliat Care; 2014 Dec; 8(4):328-33. PubMed ID: 25111255
[TBL] [Abstract][Full Text] [Related]
42. The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia/cachexia.
Cella DF; VonRoenn J; Lloyd S; Browder HP
Qual Life Res; 1995 Jun; 4(3):221-31. PubMed ID: 7613532
[TBL] [Abstract][Full Text] [Related]
43. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122).
Berk L; James J; Schwartz A; Hug E; Mahadevan A; Samuels M; Kachnic L;
Support Care Cancer; 2008 Oct; 16(10):1179-88. PubMed ID: 18293016
[TBL] [Abstract][Full Text] [Related]
44. Managing cancer-related anorexia/cachexia.
Mantovani G; Macciò A; Massa E; Madeddu C
Drugs; 2001; 61(4):499-514. PubMed ID: 11324680
[TBL] [Abstract][Full Text] [Related]
45. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia.
Dewey A; Baughan C; Dean T; Higgins B; Johnson I
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD004597. PubMed ID: 17253515
[TBL] [Abstract][Full Text] [Related]
46. Ten years of Croatian national guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome - Evaluation of awareness and implementation among Croatian oncologists.
Krznaric Ž; Juretic A; Domislovic V; Barisic A; Kekez D; Vranesic Bender D
Clin Nutr ESPEN; 2019 Oct; 33():202-206. PubMed ID: 31451262
[TBL] [Abstract][Full Text] [Related]
47. Carnitine administration reduces cytokine levels, improves food intake, and ameliorates body composition in tumor-bearing rats.
Laviano A; Molfino A; Seelaender M; Frascaria T; Bertini G; Ramaccini C; Bollea MR; Citro G; Rossi Fanelli F
Cancer Invest; 2011 Dec; 29(10):696-700. PubMed ID: 22085273
[TBL] [Abstract][Full Text] [Related]
48. Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal.
Lelli G; Montanari M; Gilli G; Scapoli D; Antonietti C; Scapoli D
J Chemother; 2003 Jun; 15(3):220-5. PubMed ID: 12868546
[TBL] [Abstract][Full Text] [Related]
49. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.
Goldberg RM; Loprinzi CL; Mailliard JA; O'Fallon JR; Krook JE; Ghosh C; Hestorff RD; Chong SF; Reuter NF; Shanahan TG
J Clin Oncol; 1995 Nov; 13(11):2856-9. PubMed ID: 7595749
[TBL] [Abstract][Full Text] [Related]
50. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
Gordon JN; Trebble TM; Ellis RD; Duncan HD; Johns T; Goggin PM
Gut; 2005 Apr; 54(4):540-5. PubMed ID: 15753541
[TBL] [Abstract][Full Text] [Related]
51. Clinical anticachexia treatments.
Tisdale MJ
Nutr Clin Pract; 2006 Apr; 21(2):168-74. PubMed ID: 16556927
[TBL] [Abstract][Full Text] [Related]
52. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
53. Clinical evaluation and optimal management of cancer cachexia.
Tuca A; Jimenez-Fonseca P; Gascón P
Crit Rev Oncol Hematol; 2013 Dec; 88(3):625-36. PubMed ID: 23953794
[TBL] [Abstract][Full Text] [Related]
54. HIV-related cachexia: potential mechanisms and treatment.
Von Roenn JH; Roth EL; Craig R
Oncology; 1992; 49 Suppl 2():50-4. PubMed ID: 1461629
[TBL] [Abstract][Full Text] [Related]
55. Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.
Hunter CN; Abdel-Aal HH; Elsherief WA; Farag DE; Riad NM; Alsirafy SA
J Pain Symptom Manage; 2021 Dec; 62(6):1207-1215. PubMed ID: 34051293
[TBL] [Abstract][Full Text] [Related]
56. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.
Mantovani G; Macciò A; Madeddu C; Serpe R; Antoni G; Massa E; Dessì M; Panzone F
J Mol Med (Berl); 2010 Jan; 88(1):85-92. PubMed ID: 19802504
[TBL] [Abstract][Full Text] [Related]
57. Advances in pharmacologic strategies for cancer cachexia.
Madeddu C; Mantovani G; Gramignano G; Macciò A
Expert Opin Pharmacother; 2015; 16(14):2163-77. PubMed ID: 26330024
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological treatment of cachexia: any progress?
Bruera E
Support Care Cancer; 1998 Mar; 6(2):109-13. PubMed ID: 9540168
[TBL] [Abstract][Full Text] [Related]
59. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women.
Wright TJ; Dillon EL; Durham WJ; Chamberlain A; Randolph KM; Danesi C; Horstman AM; Gilkison CR; Willis M; Richardson G; Hatch SS; Jupiter DC; McCammon S; Urban RJ; Sheffield-Moore M
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):482-496. PubMed ID: 29654645
[TBL] [Abstract][Full Text] [Related]
60. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management.
Gadducci A; Cosio S; Fanucchi A; Genazzani AR
Anticancer Res; 2001; 21(4B):2941-7. PubMed ID: 11712791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
